問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Division of Urology

Division of Colorectal Surgery

Division of General Surgery

Linkou Chang Gung Medical Foundation (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

National Taiwan University Hospital
Taipei Veterans General Hospital

更新時間：2023-09-19

蘇祐立Su, Yu-Li
  • Principal Investigator
  • Clinical Trial Experience (year) 18 years 1 個月

  • yolisu@cgmh.org.tw

Recruiting Trial

99Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蘇祐立

List

196Cases

2025-09-01 - 2031-06-30

Not yet recruiting
A phase 3, open-label, randomized trial was conducted to evaluate the efficacy and safety of RLY-2608 + Fulvestrant compared to Capivasertib + Fulvestrant in patients with PIK3CA-mutated hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer that relapsed or progressed during or after CDK4/6 inhibitor therapy.

  • Condition/Disease

    Locally advanced or metastatic breast cancer

  • Test Drug

    Capivasertib Capivasertib Fulvestrant RLY-2608

Participate Sites
6Sites

Recruiting6Sites

2025-09-01 - 2027-05-31

Phase I/II

Active
A first-in-human dose escalation and expansion trial of BDC-4182 as a single agent in patients with advanced gastric and gastroesophageal cancer in stage 1/2.

  • Condition/Disease

    Advanced gastric cancer, advanced gastroesophageal cancer

  • Test Drug

    BDC-4182

Participate Sites
6Sites

Recruiting6Sites

2025-09-15 - 2036-04-30

Phase III

Not yet recruiting
A randomized, double-blind, placebo-controlled phase III trial is evaluating adjuvant saruparib (AZD5305) (EvoPAR-Prostate02) in patients with locally high-risk prostate cancer of the breast cancer gene mutation (BRCAm) who are currently receiving radiation therapy and androgen deprivation therapy.

  • Condition/Disease

    Metastasis-free survival (MFS) [Time range: approximately 93 months] - MFS is defined as the time elapsed from the date of randomization until the day of first diagnosis of distant metastasis as assessed by BICR (confirmed by standard clinical imaging [CT/MRI and bone scan, or PSMA-PET]) or death from any cause.

  • Test Drug

    AZD5305

Participate Sites
8Sites

Recruiting8Sites

2025-02-07 - 2032-12-31

Phase I/II

Active
A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E

  • Condition/Disease

    Esophageal Squamous Cell Carcinoma

  • Test Drug

    凍晶注射劑 注射劑 注射劑 注射劑 注射劑 注射劑

Participate Sites
8Sites

Recruiting8Sites

2024-11-01 - 2029-12-31

Phase III

Active
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy

  • Condition/Disease

    Colorectal Neoplasms

  • Test Drug

    Injectable solution Injectable preparation Injectable preparation

Participate Sites
7Sites

Not yet recruiting3Sites

Recruiting4Sites

2025-02-03 - 2029-12-23

Not yet recruiting
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of TPST-1120 in Combination With Atezolizumab Plus Bevacizumab Compared With Placebo Plus Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Not Previously Treated With Systemic Therapy

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2019-05-01 - 2029-12-31

Phase III

Completed
A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma and Complete Radiological Response After Surgical Resection or Local Ablation (KEYNOTE-937)

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    Injectable

Participate Sites
6Sites

Recruiting3Sites

Terminated3Sites

2025-10-01 - 2029-06-30

Phase III

Active
A phase 3, randomized, multicenter, open-label study was conducted to investigate the use of IDRX-42 (GSK6042981) versus Sunitinib in participants with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) who had received imatinib treatment (StrateGIST 3).

  • Condition/Disease

    Metastatic and/or unresectable gastrointestinal stromal tumors (GISTs) following treatment with imatinib.

  • Test Drug

    IDRX-42 (GSK6042981) Sunitinib

Participate Sites
6Sites

Recruiting6Sites

2025-10-01 - 2029-12-31

Active
A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Condition/Disease

    Squamous Cell Carcinoma of Head and Neck

  • Test Drug

    Injectable drugs Subcutaneous injections Injectable drugs Injectable drugs Injectable drugs

Participate Sites
7Sites

Recruiting7Sites

2025-10-01 - 2028-12-31

Phase I/II

Active
An Open-label, Multicenter, Phase 1/2 Study Exploring the Safety and Efficacy of ABT-301 in Combination With Tislelizumab and Bevacizumab in Participants With Proficient Mismatch Repair (pMMR)/Non-Microsatellite Instability-High (Non-MSI-H) Locally Advanced or Metastatic Colorectal Cancer (mCRC)

  • Condition/Disease

    Colorectal Cancer (Diagnosis)

  • Test Drug

    Capsules Intravenous Infusion Intravenous Infusion Capsules

Participate Sites
7Sites

Recruiting7Sites

1 2 3 4 5 20
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB